AU2001280764A1 - Drug delivery system for enhanced bioavailability of hydrophobic active ingredients - Google Patents

Drug delivery system for enhanced bioavailability of hydrophobic active ingredients

Info

Publication number
AU2001280764A1
AU2001280764A1 AU2001280764A AU8076401A AU2001280764A1 AU 2001280764 A1 AU2001280764 A1 AU 2001280764A1 AU 2001280764 A AU2001280764 A AU 2001280764A AU 8076401 A AU8076401 A AU 8076401A AU 2001280764 A1 AU2001280764 A1 AU 2001280764A1
Authority
AU
Australia
Prior art keywords
delivery system
drug delivery
active ingredients
hydrophobic active
enhanced bioavailability
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001280764A
Inventor
Joshua Gatts
Charles Hsiao
Ching-Ling Teng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Impax Laboratories LLC
Original Assignee
Impax Laboratories LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Impax Laboratories LLC filed Critical Impax Laboratories LLC
Publication of AU2001280764A1 publication Critical patent/AU2001280764A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
AU2001280764A 2000-08-09 2001-07-26 Drug delivery system for enhanced bioavailability of hydrophobic active ingredients Abandoned AU2001280764A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09635234 2000-08-09
US09/635,234 US6531158B1 (en) 2000-08-09 2000-08-09 Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
PCT/US2001/023401 WO2002011699A1 (en) 2000-08-09 2001-07-26 Drug delivery system for enhanced bioavailability of hydrophobic active ingredients

Publications (1)

Publication Number Publication Date
AU2001280764A1 true AU2001280764A1 (en) 2002-02-18

Family

ID=24546994

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001280764A Abandoned AU2001280764A1 (en) 2000-08-09 2001-07-26 Drug delivery system for enhanced bioavailability of hydrophobic active ingredients

Country Status (4)

Country Link
US (2) US6531158B1 (en)
AU (1) AU2001280764A1 (en)
TW (1) TWI285116B (en)
WO (1) WO2002011699A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL130602A0 (en) 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
JPWO2002069957A1 (en) * 2001-03-01 2004-07-02 グレラン製薬株式会社 Fenofibrate-containing composition
JP2005531521A (en) * 2002-03-26 2005-10-20 テバ ファーマシューティカル インダストリーズ リミティド Drag fine particles
WO2004028506A1 (en) * 2002-09-24 2004-04-08 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of fenofibrate having high bioavailability
CN100473378C (en) * 2002-12-17 2009-04-01 阿伯特有限及两合公司 Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof
EP1829541A1 (en) * 2002-12-17 2007-09-05 Abbott GmbH & Co. KG Formulation comprising fenofibric acid or a physiologically acceptable salt thereof
BE1015641A4 (en) * 2003-05-26 2005-07-05 Mariani Jean Paul Micronization 70.
EP1559419A1 (en) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
KR101499822B1 (en) 2006-01-20 2015-03-06 오클루스 이노바티브 사이언시즈 인코포레이티드 Methods of treating or preventing sinusitis with oxidative reductive potential water solution
CA2644905A1 (en) * 2006-03-06 2007-09-13 Teva Pharmaceutical Industries Ltd. Ezetimibe compositions
EP2029110B1 (en) 2006-06-06 2011-08-31 Tibotec Pharmaceuticals Process for preparing spray dried formulations of tmc125
KR20090045205A (en) * 2006-06-26 2009-05-07 뮤추얼 파마슈티컬 컴퍼니 아이엔씨. Active agent formulations, methods of making, and methods of use
JP2010513325A (en) * 2006-12-21 2010-04-30 アルファファーム ピーティーワイ リミテッド Pharmaceutical composition
WO2008104846A2 (en) * 2007-02-26 2008-09-04 Wockhardt Research Centre Pharmaceutical compositions of fenofibrate
US9180110B2 (en) 2007-02-26 2015-11-10 Wockhardt Ltd. Pharmaceutical compositions of fenofibrate
WO2009042114A2 (en) 2007-09-21 2009-04-02 The Johns Hopkins University Phenazine derivatives and uses thereof
BRPI0917444A2 (en) 2008-08-15 2015-12-01 Depomed Inc gastric retention pharmaceutical compositions for the treatment and prevention of snc diseases
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
US20100166857A1 (en) * 2008-12-30 2010-07-01 Dong Yan Pharmaceutical dosage forms and methods of manufacturing same
FR2943539B1 (en) * 2009-03-31 2011-07-22 Ethypharm Sa PHARMACEUTICAL COMPOSITION COMPRISING A IMMUNOSUPPRESSIVE MACROLIDE OF THE LIMUS FAMILY.
CN102480972B (en) 2009-06-15 2014-12-10 奥古露丝创新科学公司 Solution containing hypochlorous acid and methods of using same
KR101202994B1 (en) * 2010-04-12 2012-11-21 한미사이언스 주식회사 Oral pharmaceutical composition comprising fenofibric acid and an alkalifying agent
WO2014091318A1 (en) 2012-12-11 2014-06-19 Lupin Atlantis Holdings, S.A. Reduced dose pharmaceutical compositions of fenofibrate
WO2018187849A1 (en) * 2017-04-13 2018-10-18 Pharmako Biotechnologies Pty Limited Cold-water-dispersible chemical delivery system

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639637A (en) 1968-04-23 1972-02-01 Richardson Merrell Inc Water dispersible diethylstilbestrol compositions
US4013785A (en) 1975-03-21 1977-03-22 Bristol-Myers Company Apap tablet containing fumed silica and process for manufacturing same
GB1579818A (en) 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
US4153678A (en) * 1978-07-17 1979-05-08 American Cyanamid Company Levamisole effervescent tablets
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
FR2494112B1 (en) 1980-11-19 1986-01-10 Laruelle Claude
DE3107933A1 (en) 1981-03-02 1982-09-16 Cassella Ag, 6000 Frankfurt SUBSTITUTED 3-AMINO-SYDNONIMINE, METHOD FOR THE PRODUCTION AND USE THEREOF
DE3247118A1 (en) 1982-12-20 1984-06-20 Cassella Ag, 6000 Frankfurt NEW SUBSTITUTED 1,4-DIHYDROPYRIDINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICINAL PRODUCT
FR2557459B1 (en) 1984-01-02 1986-05-30 Lhd Lab Hygiene Dietetique POLYCAPROLACTONE-BASED INERT MATRIX FOR ORAL ADMINISTRATION OF A MEDICAMENT, AND METHOD FOR PREPARING THE GALENIC FORM COMPRISING THE SAME
US4721709A (en) 1984-07-26 1988-01-26 Pyare Seth Novel pharmaceutical compositions containing hydrophobic practically water-insoluble drugs adsorbed on pharmaceutical excipients as carrier; process for their preparation and the use of said compositions
EP0179583A1 (en) 1984-10-04 1986-04-30 Merck & Co. Inc. A system for enhancing the water dissolution rate and solubility of poorly soluble drugs
EP0232254A1 (en) 1985-07-24 1987-08-19 SETH, Pyare Oxazepam containing pharmaceutical composition
US4716033A (en) 1986-03-27 1987-12-29 Warner-Lambert Company Medicament adsorbates with surfactant and their preparation
FR2602423B1 (en) 1986-08-08 1989-05-05 Ethypharm Sa PROCESS FOR THE PREPARATION OF A FENOFIBRATE-BASED MEDICINAL PRODUCT, OBTAINED BY THIS PROCESS
US4859703A (en) 1987-06-15 1989-08-22 Warner-Lambert Company Lipid regulating compositions
FR2627696B1 (en) * 1988-02-26 1991-09-13 Fournier Innovation Synergie NEW GALENIC FORM OF FENOFIBRATE
SE8803935L (en) * 1988-10-31 1990-05-01 Kabivitrum Ab LAEKEMEDELSKOMPOSITION
US5228400A (en) * 1991-07-30 1993-07-20 Luke William J Planting tool
TW355683B (en) * 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
US5948438A (en) 1995-01-09 1999-09-07 Edward Mendell Co., Inc. Pharmaceutical formulations having improved disintegration and/or absorptivity
US5545628A (en) * 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
FR2737121B1 (en) 1995-07-27 1997-10-03 Cl Pharma NEW GALENIC FORMULATIONS OF FENOFIBRATE AND THEIR APPLICATIONS
US5769934A (en) 1997-01-15 1998-06-23 Fmc Corporation Method for producing microcrystalline cellulose
FR2758459B1 (en) * 1997-01-17 1999-05-07 Pharma Pass FENOFIBRATE PHARMACEUTICAL COMPOSITION HAVING HIGH BIODAVAILABILITY AND PROCESS FOR PREPARING THE SAME
CA2214895C (en) * 1997-09-19 1999-04-20 Bernard Charles Sherman Improved pharmaceutical composition comprising fenofibrate
FR2774591B1 (en) * 1998-02-12 2000-05-05 Lipha PHARMACEUTICAL COMPOSITION COMPRISING THE ASSOCIATION OF METFORMIN AND FIBRATE AND THE USE THEREOF FOR THE PREPARATION OF MEDICINES FOR REDUCING HYPERGLYCEMIA
BR9908911A (en) * 1998-03-19 2001-10-02 Bristol Myers Squibb Co Biphasic system and distribution process by controlled release of high solubility pharmaceutical substances
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
CA2270306C (en) * 1999-04-27 2000-09-26 Bernard Charles Sherman Pharmaceutical compositions comprising co-micronized fenofibrate

Also Published As

Publication number Publication date
WO2002011699A1 (en) 2002-02-14
US6531158B1 (en) 2003-03-11
TWI285116B (en) 2007-08-11
US20030138496A1 (en) 2003-07-24

Similar Documents

Publication Publication Date Title
AU2001280764A1 (en) Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
AU2002216701A1 (en) Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
AU4996300A (en) Method of electroporation-enhanced delivery of active agents
AU4334700A (en) Pharmaceutical dosage form for pulsatile delivery of methylphenidate
EP1246608A4 (en) Pharmaceutical formulations for the delivery of drugs having low aqueous solubility
AU2001283563A1 (en) Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
AU2879100A (en) Formulation and system for intra-oral delivery of pharmaceutical agents
AU6168699A (en) Non-compliant system for delivery of implant material
AU2513900A (en) Drug dosage unit for buccal administration of steroidal active agents
AU2002323151A1 (en) Application of lipid vehicles and use for drug delivery
EP1392241A4 (en) System for osmotic delivery of pharmaceutically active agents
AU2001234114A1 (en) Drugs containing combined active ingredients
AU9223098A (en) Dosage form comprising means for changing drug delivery shape
AU2002343555A1 (en) Eutectic-based self-nanoemulsified drug delivery system
SI1608362T1 (en) Stabilized pharmaceutical preparation comprising an amorphous active substance
AU2001277171A1 (en) Catheter for target specific drug delivery
AU2001238346A1 (en) Modification of biopolymers for improved drug delivery
AU2003301444A1 (en) System for delivery of active substances
AU2001227030A1 (en) Pharmaceutical composition for controlled release of an active ingredient
AU2001270963A1 (en) Transdermal drug delivery system
AU6386801A (en) System for the release of active ingredients
IL154268A0 (en) Improved solid pharmaceutical dosage formulation of hydrophobic drugs
AU3669700A (en) 4-aminobutanoic acid derivatives and drugs containing these derivatives as the active ingredient
AU2002332836A1 (en) Stabilizing catheter for protein drug delivery
AU2001260089A1 (en) Pharmaceutical compositions comprising desglymidodrine as an active drug substance